Clinical trial

Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD

NCT04606394

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-12-02

PhasePHASE4

Study timeline

Study start (actual)2020-12-02Date precision: day

Registry last updated2023-05-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

COPDunresolved

Interventions

Trelegy Ellipta 100/62.5/25Mcg Inh 30DDRUG

Ventolin 90Mcg/Actuation Inhalation AerosolDRUG

Sponsors & collaborators

Pulmonary Research Institute of Southeast Michiganlead sponsor

GlaxoSmithKlinecollaborator

Mapped research locations

Farmington HillsMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04606394 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.